Evaluating the safety and efficacy of microwave ablation in treatment of cervical metastatic lymph nodes of papillary thyroid carcinoma compared to repeat surgery. (31st December 2022)

• Record Type: Journal Article
• Authors: Tang, Wanqing; Sun, Wenhai; Niu, Xiaoyan; Wang, Xufu; Wang, Xinya; Zhang, Mingzhu; Wang, Rongling; Jiang, Wenbin; Jiang, Danni; Zhao, Cheng
• Is Part Of: International journal of hyperthermia. Volume 39:Number 1(2022)
• Page Start: 813
• Page End: 821
• Publication Date: 2022-12-31
• Subjects: Papillary thyroid carcinoma -- cervical metastatic lymph node -- microwave ablation -- repeat surgery -- ultrasound; Thermotherapy -- Periodicals; 615.832
• DOI: 10.1080/02656736.2022.2086713
• Languages: English
• ISSNs: 0265-6736

Abstract

Abstract: Objective: To evaluate the safety and efficacy of microwave ablation (MWA) versus repeat surgery for treating metastatic lymph nodes (MLNs) in papillary thyroid carcinoma (PTC). Methods: Between July 2017 and October 2020, 67 patients were enrolled in this retrospective study. 19 and 48 patients underwent MWA and repeat surgery, respectively. The primary and secondary endpoints were recurrence-free survival and complication rates, respectively. The largest diameter, volume and volume reduction ratio (VRR) were analyzed before and after MWA. The effects of different ablation powers on the largest diameter, volume and VRR were investigated. Pre and posttreatment variables (e.g., baseline characteristics, serum thyroglobulin [Tg] levels, hospitalization time, treatment costs, recurrence-free survival and complication rates) were compared between groups. Results: The largest diameter and volume postablation at each follow-up were smaller than the preablation levels ( p < 0.05), except at the 1-month follow-up ( p > 0.05). The largest diameter, volume, and VRR among the different ablation powers were not significantly different ( p > 0.05). The mean serum Tg levels and biochemical remission rates were not significantly different between the groups ( p > 0.05). Compared to reoperation, MWA had a shorter hospitalization time and lower treatment cost ( p < 0.001). Total and minor complications were higher in the reoperation group ( p < 0.05), but major complications were comparable ( p > 0.05). The recurrence-free survival rate between groups was not significantly different ( p = 0.401). The 1- and 3-year recurrence-free survival rates were comparable between the groups. Conclusions: MWA may be a safe and effective alternative to repeat surgery for treating MLNs of PTC in select patients.